Breaking News

Today
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Hot Stocks
Scholar Rock announces CEO Tony Kingsley departs company » 07:48
08/03/21
08/03
07:48
08/03/21
07:48
SRRK

Scholar Rock

$34.20 /

+2.93 (+9.37%)

Scholar Rock announced…

Story temporarily locked.
To read stories as they happen please subscribe, Login above, or return tomorrow

Get Free Trial

ShowHide Related Items >><<
SRRK Scholar Rock
$34.20 /

+2.93 (+9.37%)

SRRK Scholar Rock
$34.20 /

+2.93 (+9.37%)

06/11/21 BMO Capital
Scholar Rock coverage transferred at BMO Capital
04/26/21 Credit Suisse
Scholar Rock assumed with an Outperform at Credit Suisse
04/06/21 JPMorgan
Scholar Rock weakness overdone after TOPAZ results, says JPMorgan
01/25/21 BMO Capital
Scholar Rock price target raised to $79 from $54 at BMO Capital
SRRK Scholar Rock
$34.20 /

+2.93 (+9.37%)

  • 29
    Oct
SRRK Scholar Rock
$34.20 /

+2.93 (+9.37%)

Yesterday
On The Fly
Fly Intel: Pre-market Movers » 08:57
08/02/21
08/02
08:57
08/02/21
08:57
XCUR

Exicure

$1.34 /

-0.015 (-1.11%)

, ALKS

Alkermes

$25.90 /

+0.345 (+1.35%)

, ATCX

Atlas Technical Consultants

$8.94 /

-0.35 (-3.77%)

, GPN

Global Payments

$193.45 /

+0.08 (+0.04%)

, CRNT

Ceragon Networks

$4.00 /

+0.255 (+6.81%)

, TSEM

Tower Semiconductor

$27.85 /

+0.2 (+0.72%)

, GPRE

Green Plains

$35.33 /

+0.77 (+2.23%)

, SQ

Square

$247.09 /

-8.065 (-3.16%)

, MRIN

Marin Software

$8.26 /

+1.79 (+27.67%)

, TGTX

TG Therapeutics

$34.95 /

-0.69 (-1.94%)

, PH

Parker-Hannifin

$312.05 /

+2.38 (+0.77%)

, AFTPF

Afterpay

$73.50 /

-0.1 (-0.14%)

, MEGGF

Meggitt

$6.50 /

+ (+0.00%)

Check out this morning's…

ShowHide Related Items >><<
XCUR Exicure
$1.34 /

-0.015 (-1.11%)

TSEM Tower Semiconductor
$27.85 /

+0.2 (+0.72%)

TGTX TG Therapeutics
$34.95 /

-0.69 (-1.94%)

SQ Square
$247.09 /

-8.065 (-3.16%)

PH Parker-Hannifin
$312.05 /

+2.38 (+0.77%)

MRIN Marin Software
$8.26 /

+1.79 (+27.67%)

GPRE Green Plains
$35.33 /

+0.77 (+2.23%)

GPN Global Payments
$193.45 /

+0.08 (+0.04%)

CRNT Ceragon Networks
$4.00 /

+0.255 (+6.81%)

ATCX Atlas Technical Consultants
$8.94 /

-0.35 (-3.77%)

ALKS Alkermes
$25.90 /

+0.345 (+1.35%)

XCUR Exicure
$1.34 /

-0.015 (-1.11%)

06/11/21 BMO Capital
Exicure coverage transferred at BMO Capital
12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
ALKS Alkermes
$25.90 /

+0.345 (+1.35%)

07/29/21 Mizuho
Alkermes price target raised to $33 from $29 at Mizuho
07/06/21 Mizuho
Alkermes shares should continue to run, says Mizuho
06/07/21 Mizuho
Alkermes oncology asset underappreciated by investors, says Mizuho
06/02/21 H.C. Wainwright
Alkermes price target raised to $25 from $24 at H.C. Wainwright
ATCX Atlas Technical Consultants
$8.94 /

-0.35 (-3.77%)

01/08/21
Fly Intel: Top five analyst initiations
01/08/21 Stifel
Atlas Technical Consultants initiated with a Buy at Stifel
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
08/11/20 DA Davidson
Atlas Technical Consultants upgraded to Buy from Neutral at DA Davidson
GPN Global Payments
$193.45 /

+0.08 (+0.04%)

07/19/21 Baird
Global Payments designated as a bullish Fresh Pick at Baird
07/15/21 Evercore ISI
Global Payments added to Tactical Outperform List at Evercore ISI
06/24/21 MoffettNathanson
Negative sentiment on Payment deal stocks overdone, says MoffettNathanson
05/13/21 Jefferies
Global Payments selloff presents attractive entry point, says Jefferies
CRNT Ceragon Networks
$4.00 /

+0.255 (+6.81%)

05/04/21 Needham
Ceragon Networks upgraded to Buy from Hold at Needham
05/04/21 Needham
Ceragon Networks upgraded to Buy from Hold at Needham
03/12/21 Needham
Ceragon Networks upgraded to Hold from Underperform at Needham
03/12/21 Needham
Ceragon Networks upgraded to Hold from Underperform at Needham
TSEM Tower Semiconductor
$27.85 /

+0.2 (+0.72%)

02/18/21 Craig-Hallum
Tower Semiconductor price target raised to $40 from $35 at Craig-Hallum
02/01/21 Craig-Hallum
Tower Semiconductor price target raised to $35 from $27 at Craig-Hallum
01/19/21 Credit Suisse
Tower Semiconductor upgraded to Outperform from Neutral at Credit Suisse
01/18/21 Credit Suisse
Tower Semiconductor upgraded to Outperform from Neutral at Credit Suisse
GPRE Green Plains
$35.33 /

+0.77 (+2.23%)

07/15/21 BofA
BofA starts Green Plains at Buy, sees 46% upside
07/15/21 BofA
Green Plains initiated with a Buy at BofA
07/15/21 Evercore ISI
Green Plains initiated with an In Line at Evercore ISI
07/14/21 Evercore ISI
Green Plains initiated with an In Line at Evercore ISI
SQ Square
$247.09 /

-8.065 (-3.16%)

08/02/21 Stephens
Square buying Afterpay has 'direct implications' for Affirm, says Stephens
08/02/21 Deutsche Bank
Square deal expands addressable market 'considerably,' says Deutsche Bank
08/02/21 Piper Sandler
Square acquisition of Afterpay brings 'powerful opportunity,' says Piper
08/02/21 Oddo BHF
Square upgraded to Outperform from Neutral at Oddo BHF
MRIN Marin Software
$8.26 /

+1.79 (+27.67%)

TGTX TG Therapeutics
$34.95 /

-0.69 (-1.94%)

04/20/21
Fly Intel: Top five analyst initiations
04/20/21 Goldman Sachs
TG Therapeutics initiated with a Neutral at Goldman Sachs
04/19/21 Cantor Fitzgerald
TG Therapeutics price target raised to $74 from $68 at Cantor Fitzgerald
04/19/21 H.C. Wainwright
TG Therapeutics price target raised to $89 from $79 at H.C. Wainwright
PH Parker-Hannifin
$312.05 /

+2.38 (+0.77%)

06/23/21
Fly Intel: Top five analyst upgrades
06/23/21 KeyBanc
KeyBanc upgrades Parker-Hannifin to Overweight on 'multiyear upcycle'
06/23/21 KeyBanc
Parker-Hannifin upgraded to Overweight from Sector Weight at KeyBanc
06/11/21 Baird
Parker-Hannifin end markets accelerating growth mode, says Baird
AFTPF Afterpay
$73.50 /

-0.1 (-0.14%)

08/01/21 BTIG
Square makes big move into 'buy now, pay later,' says BTIG
MEGGF Meggitt
$6.50 /

+ (+0.00%)

07/19/21 Morgan Stanley
Meggitt price target raised to 470 GBp from 455 GBp at Morgan Stanley
07/15/21 UBS
Meggitt price target lowered to 473 GBp from 491 GBp at UBS
07/12/21 Barclays
Meggitt price target lowered to 491 GBp from 533 GBp at Barclays
07/08/21 JPMorgan
Meggitt price target lowered to 455 GBp from 480 GBp at JPMorgan
XCUR Exicure
$1.34 /

-0.015 (-1.11%)

TSEM Tower Semiconductor
$27.85 /

+0.2 (+0.72%)

TGTX TG Therapeutics
$34.95 /

-0.69 (-1.94%)

SQ Square
$247.09 /

-8.065 (-3.16%)

PH Parker-Hannifin
$312.05 /

+2.38 (+0.77%)

MRIN Marin Software
$8.26 /

+1.79 (+27.67%)

GPRE Green Plains
$35.33 /

+0.77 (+2.23%)

GPN Global Payments
$193.45 /

+0.08 (+0.04%)

CRNT Ceragon Networks
$4.00 /

+0.255 (+6.81%)

ALKS Alkermes
$25.90 /

+0.345 (+1.35%)

  • 25
    Feb
  • 15
    Dec
  • 14
    Aug
SQ Square
$247.09 /

-8.065 (-3.16%)

GPRE Green Plains
$35.33 /

+0.77 (+2.23%)

ATCX Atlas Technical Consultants
$8.94 /

-0.35 (-3.77%)

ALKS Alkermes
$25.90 /

+0.345 (+1.35%)

TSEM Tower Semiconductor
$27.85 /

+0.2 (+0.72%)

TGTX TG Therapeutics
$34.95 /

-0.69 (-1.94%)

SQ Square
$247.09 /

-8.065 (-3.16%)

PH Parker-Hannifin
$312.05 /

+2.38 (+0.77%)

MRIN Marin Software
$8.26 /

+1.79 (+27.67%)

GPRE Green Plains
$35.33 /

+0.77 (+2.23%)

GPN Global Payments
$193.45 /

+0.08 (+0.04%)

CRNT Ceragon Networks
$4.00 /

+0.255 (+6.81%)

ALKS Alkermes
$25.90 /

+0.345 (+1.35%)

SQ Square
$247.09 /

-8.065 (-3.16%)

MRIN Marin Software
$8.26 /

+1.79 (+27.67%)

GPN Global Payments
$193.45 /

+0.08 (+0.04%)

ATCX Atlas Technical Consultants
$8.94 /

-0.35 (-3.77%)

Recommendations
Regeneron price target raised to $741 from $729 at H.C. Wainwright » 06:11
08/02/21
08/02
06:11
08/02/21
06:11
REGN

Regeneron

$574.52 /

-7.72 (-1.33%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King raised the firm's price target on Regeneron to $741 from $729 and reiterates a Buy rating on the shares after the FDA authorized REGEN-COV to be used as a post-Covid exposure therapy in individuals with high risk for severe Covid. The FDA's decision to expand REGEN-COV's use as a post-exposure proxylaxis therapy represents a significant step in preventing potentially exposed high-risk individuals from acquiring the infection and succumbing to its complications, King tells investors in a research note.

ShowHide Related Items >><<
REGN Regeneron
$574.52 /

-7.72 (-1.33%)

REGN Regeneron
$574.52 /

-7.72 (-1.33%)

07/29/21 H.C. Wainwright
Regeneron price target raised to $729 from $703 at H.C. Wainwright
07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
REGN Regeneron
$574.52 /

-7.72 (-1.33%)

REGN Regeneron
$574.52 /

-7.72 (-1.33%)

REGN Regeneron
$574.52 /

-7.72 (-1.33%)

REGN Regeneron
$574.52 /

-7.72 (-1.33%)

Hot Stocks
Ipsen, Exicure enter exclusive collaboration agreement to explore SNAs » 05:39
08/02/21
08/02
05:39
08/02/21
05:39
XCUR

Exicure

$1.34 /

-0.015 (-1.11%)

, IPSEY

Ipsen

$26.76 /

+1.085 (+4.23%)

Ipsen (IPSEY) and Exicure…

Ipsen (IPSEY) and Exicure (XCUR) have signed an exclusive collaboration agreement to research, develop, and commercialize novel Spherical Nucleic Acids, or SNAs, as potential investigational treatments for Huntington's disease and Angelman syndrome. Oligonucleotides are synthetic structures of nucleic acids that can be used to modulate gene expression via a range of processes, including gene activation, inhibition, and splice-modulation. These molecules have demonstrated potential in many different therapeutic areas. Achieving efficient oligonucleotide delivery to target organs and tissues, including the brain, remains a major limitation to their use. Exicure's SNAs provide distinct chemical and biochemical properties to oligonucleotides. In preclinical models, SNAs have been shown to enhance the cell penetration, biodistribution and organ persistence properties of oligonucleotides, which may potentially enhance drug delivery to previously inaccessible target tissues, including deep brain regions. Under the agreement, Ipsen will receive exclusive options to license SNA-based therapeutics arising from two collaboration programs for Huntington's disease and Angelman syndrome. Ipsen will pay Exicure a cash upfront payment of $20M upon closing and Exicure will be responsible for discovery and certain pre-clinical development activities. In the event Ipsen exercises its option, Ipsen will be responsible for further development and commercialization of the licensed products. Exicure will receive a $20M upfront payment and is eligible to receive up to $1B in option exercise fees and milestone payments should Ipsen opt into both programs, as well as tiered royalties.

ShowHide Related Items >><<
XCUR Exicure
$1.34 /

-0.015 (-1.11%)

IPSEY Ipsen
$26.76 /

+1.085 (+4.23%)

XCUR Exicure
$1.34 /

-0.015 (-1.11%)

06/11/21 BMO Capital
Exicure coverage transferred at BMO Capital
12/18/20 BMO Capital
Exicure initiated with an Outperform at BMO Capital
IPSEY Ipsen
$26.76 /

+1.085 (+4.23%)

07/30/21 Credit Suisse
Ipsen price target raised to EUR 90 from EUR 75 at Credit Suisse
06/29/21 Societe Generale
Ipsen price target lowered to EUR 90 from EUR 93 at Societe Generale
06/14/21 Societe Generale
Ipsen downgraded on 'lackluster' guidance at Societe Generale
06/14/21 Societe Generale
Ipsen downgraded to Hold from Buy at Societe Generale
XCUR Exicure
$1.34 /

-0.015 (-1.11%)

Friday
Hot Stocks
Regeneron reports FDA expands authorized use of REGEN-COV » 13:46
07/30/21
07/30
13:46
07/30/21
13:46
REGN

Regeneron

$574.41 /

-7.83 (-1.34%)

Regeneron Pharmaceuticals…

Regeneron Pharmaceuticals announced that the U.S. Food and Drug Administration updated the Emergency Use Authorization, or EUA, for the investigational COVID-19 antibody cocktail REGEN-COV. The authorization now includes post-exposure prophylaxis in people at high risk for progression to severe COVID-19, who are not fully vaccinated or are not expected to mount an adequate response to vaccination, and have been exposed to a SARS-CoV-2 infected individual, or who are at high risk of exposure to an infected individual because of infection occurring in the same institutional setting, such as in nursing homes or prisons. In those who require repeat dosing for ongoing exposure, REGEN-COV can also now be administered monthly. This new indication in people aged 12 and older is in addition to the previously granted authorization to treat non-hospitalized patients. REGEN-COV is not a substitute for vaccination against COVID-19, and is not authorized for pre-exposure prophylaxis to prevent COVID-19.

ShowHide Related Items >><<
REGN Regeneron
$574.41 /

-7.83 (-1.34%)

REGN Regeneron
$574.41 /

-7.83 (-1.34%)

07/29/21 H.C. Wainwright
Regeneron price target raised to $729 from $703 at H.C. Wainwright
07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
REGN Regeneron
$574.41 /

-7.83 (-1.34%)

REGN Regeneron
$574.41 /

-7.83 (-1.34%)

REGN Regeneron
$574.41 /

-7.83 (-1.34%)

REGN Regeneron
$574.41 /

-7.83 (-1.34%)

Thursday
Recommendations
Regeneron price target raised to $729 from $703 at H.C. Wainwright » 12:58
07/29/21
07/29
12:58
07/29/21
12:58
REGN

Regeneron

$585.00 /

-1.51 (-0.26%)

, SNY

Sanofi

$51.32 /

-0.74 (-1.42%)

H.C. Wainwright analyst…

H.C. Wainwright analyst Michael King raised the firm's price target on Regeneron Pharmaceuticals (REGN) to $729 from $703 and keeps a Buy rating on the shares after the company and Sanofi (SNY) announced Dupixent met all key primary and secondary endpoints in the Phase 3 trial for chronic spontaneous urticaria. The data continues to support Dupixent's "well-established" safety profile, King tells investors in a research note. The analyst updated his model to reflect the increased probability of success for Dupixent.

ShowHide Related Items >><<
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

SNY Sanofi
$51.32 /

-0.74 (-1.42%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

REGN Regeneron
$585.00 /

-1.51 (-0.26%)

Hot Stocks
Regeneron, Sanofi announce Dupixent trial met primary and secondary endpoints » 05:53
07/29/21
07/29
05:53
07/29/21
05:53
REGN

Regeneron

$586.33 /

+5.33 (+0.92%)

, SNY

Sanofi

$52.06 /

+0.505 (+0.98%)

Regeneron (REGN) and…

Regeneron (REGN) and Sanofi (SNY) announced a pivotal Phase 3 trial evaluating Dupixent in patients with moderate-to-severe chronic spontaneous urticaria, or CSU, met its primary and all key secondary endpoints at 24 weeks. Adding Dupixent to standard-of-care antihistamines significantly reduced itch and hives for biologic-naive patients, compared to antihistamines alone in Study A, the first of two trials of the LIBERTY-CUPID clinical program. In the trial, adding Dupixent to standard-of-care antihistamines nearly doubled the reduction in itch and urticaria activity compared to standard-of-care alone (placebo) with continuous improvement out to 24 weeks. Patients experienced a 63% reduction in itch severity with Dupixent versus 35% with placebo, as measured by a 0-21 point itch severity scale, the primary endpoint in the U.S.; 65% reduction in urticaria activity severity with Dupixent versus 37% with placebo, as measured by a 0-42 point urticaria activity scale, the secondary endpoint in the U.S. The trial demonstrated safety results similar to the known safety profile of Dupixent in its approved indications. For the 24-week treatment period, the occurrence of treatment emergent adverse events were generally similar between the Dupixent and placebo groups. The most common adverse events were injection site reactions. The potential use of Dupixent in CSU and EoE is currently under clinical development, and the safety and efficacy have not been fully evaluated by any regulatory authority.

ShowHide Related Items >><<
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

07/26/21 Roth Capital
Translate Bio price target raised to $45 from $28 at Roth Capital
05/25/21 JPMorgan
Olema selloff brings 'compelling' entry point, says JPMorgan
04/30/21 Deutsche Bank
Sanofi price target raised to EUR 75 from EUR 70 at Deutsche Bank
04/29/21 Barclays
Sanofi price target raised to EUR 90 from EUR 85 at Barclays
SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

SNY Sanofi
$52.06 /

+0.505 (+0.98%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

REGN Regeneron
$586.33 /

+5.33 (+0.92%)

Over a week ago
Hot Stocks
SpringsWorks Therapeutics appoints James Cassidy as CMO » 08:09
07/27/21
07/27
08:09
07/27/21
08:09
SWTX

SpringsWorks Therapeutics

$84.77 /

+1.75 (+2.11%)

, REGN

Regeneron

$578.01 /

-8.45 (-1.44%)

SpringWorks Therapeutics…

SpringWorks Therapeutics (SWTX) announced that James Cassidy, M.D., Ph.D., has been appointed Chief Medical Officer. Cassidy succeeds Jens Renstrup, M.D., MBA, who will be leaving the company. Dr. Cassidy joins SpringWorks from Regeneron Pharmaceuticals (REGN), where he was Vice President of Oncology Strategic Program Direction.

ShowHide Related Items >><<
SWTX SpringsWorks Therapeutics
$84.77 /

+1.75 (+2.11%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

SWTX SpringsWorks Therapeutics
$84.77 /

+1.75 (+2.11%)

07/21/21 H.C. Wainwright
SpringsWorks price target raised to $136 from $124 at H.C. Wainwright
07/20/21 Goldman Sachs
SpringsWorks Therapeutics price target raised to $123 from $107 at Goldman Sachs
03/30/21 JPMorgan
SpringsWorks Therapeutics added to Analyst Focus List at JPMorgan
02/26/21 Barclays
SpringsWorks Therapeutics price target raised to $105 from $92 at Barclays
REGN Regeneron
$578.01 /

-8.45 (-1.44%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
SWTX SpringsWorks Therapeutics
$84.77 /

+1.75 (+2.11%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

  • 02
    Mar
  • 08
    Oct
REGN Regeneron
$578.01 /

-8.45 (-1.44%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

SWTX SpringsWorks Therapeutics
$84.77 /

+1.75 (+2.11%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

Hot Stocks
AstraZeneca Regeneron to commercialize new small molecule medicines for obesity » 07:04
07/27/21
07/27
07:04
07/27/21
07:04
AZN

AstraZeneca

$56.79 /

-1.44 (-2.47%)

, REGN

Regeneron

$578.01 /

-8.45 (-1.44%)

AstraZeneca (AZN)…

AstraZeneca (AZN) announced it has entered into a collaboration with Regeneron (REGN) to research, develop and commercialize small molecule compounds directed against the GPR75 target with the potential to treat obesity and related co-morbidities. The companies will evenly split research and development costs and share equally in any future potential profits. Mene Pangalos, Executive Vice President, BioPharmaceuticals R&D, AstraZeneca, said: "We are pleased to announce this important collaboration with Regeneron to identify small molecule modulators against GPR75, a newly identified target with genetic validation in metabolic disorders. Obesity and insulin resistance remain key drivers in the development of type-2 diabetes and areas of significant unmet medical need." George Yancopoulos, M.D., Ph.D., President and Chief Scientific Officer of Regeneron, added: "As experts on genetics and human biology, Regeneron is excited to join forces with the chemistry and small molecule leaders at AstraZeneca, as we seek to develop new medicines tackling the harmful and costly obesity epidemic."

ShowHide Related Items >><<
REGN Regeneron
$578.01 /

-8.45 (-1.44%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

07/21/21 Citi
AstraZeneca price target raised to 10,500 GBp from 10,000 GBp at Citi
07/13/21 Piper Sandler
Bicycle Therapeutics price target raised to $46 from $39 at Piper Sandler
06/17/21 UBS
AstraZeneca price target raised to 9,200 GBp from 8,000 GBp at UBS
06/01/21 Piper Sandler
Piper sees 'quite real' chance of Akebia's vadadustat being first HIF approved
REGN Regeneron
$578.01 /

-8.45 (-1.44%)

07/23/21 RBC Capital
Regeneron price target raised to $679 from $629 at RBC Capital
07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
REGN Regeneron
$578.01 /

-8.45 (-1.44%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

REGN Regeneron
$578.01 /

-8.45 (-1.44%)

AZN AstraZeneca
$56.79 /

-1.44 (-2.47%)

Recommendations
Regeneron price target raised to $679 from $629 at RBC Capital » 06:45
07/23/21
07/23
06:45
07/23/21
06:45
REGN

Regeneron

$587.28 /

+3.76 (+0.64%)

RBC Capital analyst…

RBC Capital analyst Kennen MacKay raised the firm's price target on Regeneron to $679 from $629 and keeps a Sector Perform rating on the shares. The analyst updates his model to include both REGN3500 & NTLA-2001, stating that he views REGN3500 as one of the company's most underappreciated late-stage pipeline assets with the potential to quickly gain blockbuster status should the currently enrolling phase 3 AERIFY-1/2 trials in COPD demonstrate statistical benefit.. MacKay adds that he models a 2025 approval with the potential for REGN3500 to achieve $3B in global risk-unadjusted sales by 2035.

ShowHide Related Items >><<
REGN Regeneron
$587.28 /

+3.76 (+0.64%)

REGN Regeneron
$587.28 /

+3.76 (+0.64%)

07/09/21 Jefferies
Aslan Pharmaceuticals initiated with a Buy at Jefferies
07/08/21 Benchmark
Regeneron price target raised to $636 from $590 at Benchmark
07/07/21 H.C. Wainwright
Silverback strikes pact with Regeneron for Libtayo, says H.C. Wainwright
06/29/21
Fly Intel: Top five analyst initiations
REGN Regeneron
$587.28 /

+3.76 (+0.64%)

REGN Regeneron
$587.28 /

+3.76 (+0.64%)

REGN Regeneron
$587.28 /

+3.76 (+0.64%)

REGN Regeneron
$587.28 /

+3.76 (+0.64%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.